Welcome to the Empowered Patient Podcast with Karen Jagoda. This show is a window into the latest innovations in applying generative AI, novel therapeutics and vaccines, and the changing dynamics in the medical and healthcare environment. One focus is on how providers, pharmaceutical companies, and payers are empowering patients. In addition, conversations are often about how providers, care facilities, pharmaceutical companies, and payers are being empowered by technology to improve patient outcomes and reduce friction across the healthcare landscape.
Popular Topics
- Virtual and digital health
- Use of AI, ML, and LLM in healthcare and drug discovery, development, trials
- Value-based healthcare
- Precision and stratified medicine
- Integration of digital technology into existing workflow and procedures
- Next-generation immuno, cell, and gene therapies
- Vaccines
- Biomarkers, sequencing, and imaging
- Rare diseases
- MedTech and medical devices
- Clinical trials
- Addressing Social Determinants of Health
- Treating chronic conditions like obesity and pain
- Clinician and staff burnout
The audience includes life science leaders, researchers, medical professionals, patient advocates, digital health entrepreneurs, patients, caregivers, healthcare solution providers, students, journalists, and investors.
Check out our new EmpoweredPatient.Solutions site where you can quickly search all of the Empowered Patient Podcast interviews by any word or phrase to identify useful resources, potential partners, and insights about the life sciences landscape.
Feb 22, 2023
Lisa Yanez is the CEO of Aerami Therapeutics, a clinical stage biopharmaceutical company focused on the rare cardiopulmonary disease pulmonary arterial hypertension. Early studies show that using this smart breath-activated inhalation delivery system to administer AER901, inhaled Imatinib reduces side effects and requires less frequent administration by those suffering from PAH.
Lisa explains, "Our company is focused on a rare disease, pulmonary arterial hypertension. There was a drug that was an oral drug that was studied before, but due to the side effects, that trial ceased. That said, if you look at the efficacy of that drug, it was one of the best-performing drugs ever for these patients. It didn't just help with symptoms. It also helped the underlying cause of the disease. What our company has decided to do is take a very intelligent inhaled patient-proven device and couple it with this product to generate the best of both worlds. What we're trying to do is helping patients live longer, but our mission is also helping patients live better."
"One of the reasons I've fallen in love with this particular condition is because it mostly impacts women of childbearing age. They go about two years not knowing what's wrong with them. They have shortness of breath, they have a lot of fatigue, they're very dizzy, and sometimes they pass out. They go to all these different doctors, and typically it does take two years, and people think they're crazy."
"Then, once they're diagnosed, there are 15 approved therapies. Even then, there's only a five to seven-year time span in terms of survival. And so, there's a lot more that needs to be done with these particular patients."
@AeramiTx #Aerami #Cardiopulmonary #RareDisease #PulmonaryArterialHypertension #PulmonaryHypertension #PAH #PH #HeartDisease #LungDisease #AER901 #InhaledTherapeutics #AER601
